96 results about "Ischemic vascular dementia" patented technology

Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The preparation method comprises the following steps: detecting the concentration of cytoplasmic acyl-coenzyme A thioester hydrolase in a sample by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method, and carrying out regression analysis through Logistic, the correlation between the serum level of the cytoplasm acyl-coenzyme A thioester hydrolase in an AD (Alzheimer's disease) patient and a vascular dementia (VD) patient and the cognitive impairment degree and the A beta 40 content is evaluated, and whether the expression of the cytoplasm acyl-coenzyme A thioester hydrolase is closely related to the AD progress or not is judged. An effective molecular marker is provided for differential diagnosis of an AD patient and a VD patient, a large number of tests prove that the cytoplasm acyl-coenzyme A thioester hydrolase is highly expressed in the AD patient, the cytoplasm acyl-coenzyme A thioester hydrolase serving as an AD serum molecular marker has high diagnostic value, and when the serum content of the cytoplasm acyl-coenzyme A thioester hydrolase is higher than 62.5 pg / ml, the cytoplasm acyl-coenzyme A thioester hydrolase can assist AD diagnosis and can also serve as an auxiliary index for distinguishing AD and VD. The kit is applied to preparation of a kit for differential diagnosis of AD and VD.

This invention discloses a compound preparation for treating vascular dementia and its preparation method. The active pharmaceutical ingredient consists of protopanaxadiol and gallic acid in a 1:1 mass ratio, and the dosage form is liposomes. The preparation method includes extraction, mixing, liposome preparation, and optional freeze-drying steps: protopanaxadiol and gallic acid are extracted and purified from ginseng rhizome and Terminalia chebula fruit, respectively. After mixing, they are combined with phospholipids and cholesterol to prepare a lipid membrane. The membrane is then homogenized by hydration, low-temperature ultrasound, and high-pressure microfluidic jet to obtain a homogeneous liposome suspension, which can be further freeze-dried into a freeze-dried powder. The 1:1 composition of protopanaxadiol and gallic acid targets multiple points on the pathological mechanism of vascular dementia, showing significant therapeutic effects and broad application prospects. This preparation uses a liposome dosage form to improve the bioavailability of the active ingredient, the preparation process parameters are controllable, the active ingredient has high purity, the liposomes have uniform particle size, high encapsulation efficiency, and good stability.

The present disclosure provides an extended-release gel formulation containing a biocompatible polymer and an angiotensin-(1-7) oligopeptide or a variant thereof. Also provided are methods of treating subjects with vascular dementia, e.g., using the formulations disclosed herein or compositions containing the same, a subject can be administered the extended-release gel formulation to treat the vascular dementia.

The invention belongs to the technical field of medicinal chemistry, and relates to a benzazepine compound or pharmaceutically acceptable salt thereof as well as a preparation method and application of the benzazepine compound, in particular to a compound with a structural general formula as shown in a formula (I). The benzoazepine compound disclosed by the invention has a remarkable curative effect on treating brain organic lesion diseases, including vascular lesion and degenerative lesion, especially vascular dementia, Alzheimer's disease and cholinergic deficiency related diseases. Formula (I).

The present invention relates to a class of monoclonal antibodies having anti–von Willebrand factor (VWF) effects, and a use thereof. A pharmaceutical composition of the monoclonal antibodies or antigen-binding fragments having anti–von Willebrand factor effects provided by the present invention can be used to reduce VWF levels in the body, thereby preventing and treating thrombotic microangiopathies having various causes (including thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and atypical hemolytic-uremic syndrome), cardiovascular disease, stroke, atherosclerosis, senile dementia, vascular dementia, and bacterial and viral infectious diseases.

Association comprising: dry extract of Bacopa monnieri, Astaxanthin, Vitamin E, L-theanine and dry extract of Centella asiatica for use as an adjuvant in the prevention of vascular dementia, as it is able to reduce the main modifiable risk factors of cognitive vascular impairment (VCI).

The invention discloses ursodesoxycholic acid and amino acid conjugates (I), pharmaceutically acceptable salts thereof, a preparation method of the ursodesoxycholic acid and amino acid conjugates, a pharmaceutical composition of the ursodesoxycholic acid and amino acid conjugates and application of the ursodesoxycholic acid and amino acid conjugates in preparation of drugs for treating and / or preventing comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

To provide an effective agent for diabetic dementia and vascular dementia.SOLUTION: This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating dementia selected from diabetic dementia and vascular dementia.SELECTED DRAWING: Figure 1

The invention discloses an aminoamide alkyl thioester compound (I), pharmaceutically acceptable salts thereof, a preparation method of the aminoamide alkyl thioester compound, a pharmaceutical composition of the aminoamide alkyl thioester compound and application of the aminoamide alkyl thioester compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses an amide alkyl thiol ester compound (I) as well as a preparation method and a pharmaceutical composition thereof, and application of the amide alkyl thiol ester compound in preparation of drugs for treating and / or preventing diseases by resisting oxidative stress, inhibiting amyloid protein aggregation and resisting neuroinflammation. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

The present disclosure provides an extended-release gel formulation containing a biocompatible polymer and an angiotensin-(1-7) oligopeptide or a variant thereof. Also provided are methods of treating subjects with vascular dementia, e.g., using the formulations disclosed herein or compositions containing the same, a subject can be administered the extended-release gel formulation to treat the vascular dementia.

The invention concerns a compound of formula (I) (I) R1═H, —CH3 or acyl group, preferably R1═—CH3R2═H or halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2═H or a pharmaceutically acceptable isomer, salt and / or solvate thereof, for use in preventing and / or treating neurodegenerative diseases when central muscarinic neurotransmission is compromised, wherein said neurodegenerative disease is selected in the group consisting of Alzheimer's Disease (AD), vascular dementia, Dementia with Lewy bodies (DLB), mixed dementia, frontotemporal lobar degeneration (FTLD), and Parkinson's disease (PD).

The invention discloses application of steroid saponin of trillium tschonoskii maxim to preparation of a medicine for treating vascular dementia, and relates to the technical field of medicines. Animal experiments prove that the berberis apiacea steroid saponin can improve the spatial reference learning function of cerebral ischemia rats, improve the spatial reference memory function of the cerebral ischemia rats and enhance the long-term memory function of the cerebral ischemia rats. In addition, brain tissue damage and white matter structure damage of rats suffering from cerebral ischemia can be relieved, axonal myelin sheath microstructure reconstruction and white matter fiber reconstruction of the rats suffering from cerebral ischemia are promoted, and myelin sheath regeneration of rats suffering from vascular dementia is promoted. Network pharmacological analysis finds that the age grass total steroid saponin has a wide regulation effect on OPCs and OLs cell components and molecular functions, and further, OPCs differentiation myelin sheath inhibition related factors are regulated and controlled, and white matter myelin sheath regeneration is promoted.

The present invention relates to a C-17 carbonyl-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C-17 carbonyl-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2 activator, and preparation of a medicament for treating / preventing diseases. The diseases comprise cerebral small vascular disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, schizophrenic cognitive impairment, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc., or other disease states and conditions which are obvious to a person skilled in the art. Also provided are a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition containing same.

The invention provides application of a salidroside derivative in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion, and belongs to the technical field of biological medicine. The invention discloses application of a salidroside derivative SHPL-49 in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion. The SHPL-49 can effectively improve the learning and memory functions after brain injury, recover the exercise coordination ability, relieve corpus callosum region myelin sheath loss above the hippocampus region and further protect the brain-sea horse region synapses. The SHPL-49 has the efficacy of treating the vascular cognitive impairment and the vascular dementia. According to the application, the medical application of the SHPL-49 is widened, and a new way is provided for treating cognitive impairment diseases caused by cerebrovascular lesion.

This invention discloses the application of total small molecules of Polygonatum cyrtonema in the preparation of drugs for treating vascular dementia, belonging to the field of natural medicine technology. This invention obtains total small molecules of Polygonatum cyrtonema through a combination of water extraction and alcohol precipitation with macroporous adsorption resin purification. Experiments using a rat model of vascular dementia showed that these total small molecules of Polygonatum cyrtonema effectively improved the degree of neurological function impairment and learning and memory abilities in rats, indicating that the total small molecules of Polygonatum cyrtonema prepared by this invention can effectively treat vascular dementia, providing a new drug source and treatment method for clinical vascular dementia treatment.

This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating dementia selected from diabetic dementia and vascular dementia.

The invention relates to the technical field of drug dose screening, in particular to a method for screening the optimal dose of metformin for treating vascular dementia by using an OGD / R-SHSY5Y cell model, which comprises the following steps: constructing the OGD / R-SHSY5Y cell model to simulate the pathological state of vascular dementia; setting a control group, an OGD / R model group and a metformin treatment group with different concentrations, and additionally arranging a pathway inhibitor verification group; the cell proliferation activity is detected through a CCK8 method, the cell apoptosis rate is detected through an Annexin-V-FITC / PI double staining method, expression of apoptosis-related genes and key genes is detected through a qPCR method and a Western blot method, and the inflammatory factor level is detected through an ELISA method. By integrating multi-dimensional detection results, the optimal dosage of the metformin, which not only can significantly improve cell viability and inhibit cell apoptosis, but also can effectively regulate and control key gene expression and inflammatory factor balance, is screened out. Through multi-index collaborative detection and pathway mechanism verification, accurate screening of the optimal dose of the metformin for treating vascular dementia is realized.

The invention discloses application of C1INH protein in preparation of drugs for preventing and treating brain aging, Alzheimer's disease and vascular dementia, and relates to the field of biomedicine. In particular relates to a C1INH protein or a coding gene SERPING1 of the C1INH protein as a plasma biomarker and a therapeutic target for distinguishing the Alzheimer's disease from physiological brain aging, and application of the C1INH protein or the coding gene SERPING1 in preparation of products for evaluating brain aging and / or related states of the Alzheimer's disease and / or application of the C1INH protein or the coding gene SERPING1 in preparation of drugs for preventing and treating the brain aging, the Alzheimer's disease and vascular dementia. The C1INH protein has an amino acid sequence as shown in SEQ ID NO: 1, and the SERPING1 gene has a nucleic acid sequence as shown in SEQ ID NO: 2.

The invention discloses application of a biomarker combination in a biological sample to preparation of a vascular dementia detection product. The biomarker combination is prepared from phenylacetylurea, 3-methyl-2 (1H)-quinoxaline, pyruvic acid, L-cystine and 4-methylene glutamic acid. The applicant carries out regression analysis on the five metabolites and detects the expression level of the five metabolites between a healthy group and a disease group, the result shows that except the area of 4-methyleneglutamic acid under an AUC curve is 0.917, the areas of the other four metabolites under the AUC curve are all 1, extremely high specificity and sensitivity are shown, and the application prospect is wide. The method can be used for preparing related detection products for diagnosis or auxiliary diagnosis of vascular dementia.

BAG3 protein is used in the treatment of, for example, is Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington disease, Lewy body disease, vascular dementia, mixed dementia and Traumatic Brain Injury, for example, complicated by Chronic Traumatic Encephalopathy (CTE). Therapeutically effective BAG3 compositions, BAG3 uses and BAG3 methods of treatment are described.

The application relates to the technical field of medicines, and particularly discloses a use of (2,4-dichlorophenyl)methylsulfenyl methane amidine and salts thereof. Specifically, the application finds that (2,4-dichlorophenyl)methylsulfenyl methane amidine and its applicable medicinal derivatives can significantly enhance memory, improve the survival rate of neuron cells of patients or promote the regeneration of neuron processes of patients, and can be used for preparing medicines and health products for treating neurological diseases (such as Alzheimer's disease, vascular dementia or Lewy body dementia).

The present invention provides an α,β-unsaturated amide compound, a preparation method thereof, a pharmaceutical composition and uses. Specifically, the present invention provides a compound represented by the following formula I, wherein the definition of each group is as described in the specification. The compound can be prepared as a compound for improving cerebral blood flow and as a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia, and stroke. General formula I: TIFF2025521917000044.tif22170

This invention discloses a traditional Chinese medicine composition for treating vascular dementia, its preparation method, and its application, belonging to the field of traditional Chinese medicine technology. It includes the following raw medicinal materials: Rehmannia glutinosa (processed), Dioscorea opposita, Cornus officinalis (processed with wine), Alisma plantago-aquatica, Poria cocos, Paeonia suffruticosa, Cinnamomum cassia, Aconitum carmichaelii (processed), Acorus tatarinowii, Polygala tenuifolia (processed), Curcuma longa (processed with vinegar), Tortoise shell glue, Cervi cornu glue, Achyranthes bidentata, Cuscuta chinensis (processed with salt), Gastrodia elata, Taxillus chinensis, and Eucommia ulmoides (processed with salt). This invention also discloses the preparation method and application of the above-mentioned traditional Chinese medicine composition. The beneficial effects of this invention are: Based on the Shenqi Wan formula and combined with traditional Chinese medicine theory, this application yields a novel traditional Chinese medicine composition for treating vascular dementia. This composition can significantly improve symptoms such as cognitive decline and slow thinking in patients with vascular dementia, effectively delaying the rapid progression of the disease and providing a new treatment option for patients with vascular dementia.

A C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2-Leap1 decoupling agent, and a use of the compound in the preparation of a medicament for preventing and / or treating diseases in a patient, the diseases comprising cerebral small vessel disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, cognitive impairment in schizophrenia, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc.

The present invention discloses a traditional Chinese medicine composition for treating senile and vascular dementia, its preparation method and application. The traditional Chinese medicine composition comprises the following raw materials by weight: 5-140 parts by weight of astragalus membranaceus, 5-40 parts by weight of salvia miltiorrhiza, 1-20 parts by weight of ginseng, 2-30 parts by weight of polygonatum sibiricum, 1-20 parts by weight of angelica sinensis, 3-25 parts by weight of hawthorn, 2-30 parts by weight of processed polygonum multiflorum, 2-30 parts by weight of wolfberry fruit, 1-20 parts by weight of polygala tenuifolia, 2-30 parts by weight of acorus tatarinowii, 1-20 parts by weight of pheretima. The present invention has the effects of supplementing qi and activating blood circulation, improving intelligence and strengthening the brain, and is mainly used for treating cerebrovascular dementia of qi deficiency and blood stasis type. It can improve the learning and memory abilities of senile dementia and vascular dementia, increase the cerebral blood flow of vascular dementia, reduce the cerebrovascular resistance, prolong the survival time of cerebral ischemia and hypoxia, and has obvious inhibitory effects on the increased cerebrovascular permeability caused by cerebral hypoxia and the increased brain index.